T he antiarrhythmic effect of type I agents such as lidocaine is most likely related to their ability to slow conduction by effecting sodium channel blockade. The molecular mechanism of this pharmacologic effect is as yet unclear. The data from numerous electrophysiologic experiments have led to the concept that type I drugs bind reversibly to a single site associated with the cardiac sodium channel (e.g., Hondeghem and Katzung 1 and Grant et al 2 ). In the modulated receptor hypothesis, there are two proposed mechanisms by which drug binding to the channel could block sodium influx: drugs bound to the activated state might directly block sodium influx, and drugs bound to the inactivated state might slow recovery of the channel from the inactivated state, thereby reducing the number of channels available for activation. Despite the general acceptance of the notion based on electrophysiologic data (e.g., Clarkson and Hondeghem 3 ) that type 1 drugs interact with the sodium channel, there is as yet no biochemical evidence that a specific binding site exists for these drugs associated with the sodium channel.
These theories presuppose an interaction between small ligands (drugs) and a macromolecule (the sodium channel). The development of radiolabelled neurotoxins has provided a biochemical approach to the structure and function of the nerve sodium channel and its inhibitory ligands, the local anesthetics. 4 " 6 Alkaloid toxins such as batrachotoxin and aconitine cause persistent activation of the sodium channel by binding preferentially to, and stabilizing, the activated state of the channel. 78 The polypeptide sea anemone toxin (ATX II) enhances persistent activation by alkaloid toxins through an allosteric mechanism that enhances alkaloid toxin binding. A tritiated derivative of batrachotoxin, [ 3 H]batrachotoxinin A 20a-benzoate 4 (f 3 H]BTXB) has been used to study the interaction of local anesthetics with the nerve channel. 56 The local anesthetics allosterically inhibit alkaloid toxin binding apparently by binding to, and stabilizing, the inactivated state.
In a separate report, we described the binding of [ 3 H]BTXB and ATX II to sodium channels on freshly isolated, adult rat cardiomyocytes. 9 The toxins bind to specific, saturable sites in a manner very similar to their binding to nerve sodium channels. pH]BTXB binding was stimulated by ATX II and inhibited by other alkaloid toxins (e.g., aconitine). Furthermore, a proportion of the [ 3 H]BTXB binding was voltage-sensitive as would be expected if binding were to a voltagesensitive sodium channel.
The purpose of this report was to determine whether type I drugs inhibited [ 3 H]BTXB binding in a fashion consistent with their binding to a specific receptor site on cardiac myocytes.' 0 " In particular, the purpose was to determine whether the drug effect was saturable, reversible, and stereospecific and whether it occurred at pharmacologically relevant concentrations with the same rank order of potency in vitro as in vivo.
Materials and Methods

Myocyte Preparation
Cardiac myocytes were isolated from adult male Sprague-Dawley rats (200-250 g) using the method of Kryski et al. 12 Rats were killed by cervical dislocation and the heart rapidly removed. The aorta was cannulated, and the heart was perfused retrograde in a Langendorff perfusion apparatus. The heart was perfused and later incubated with a series of solutions that were equilibrated with 95% O 2 -5% CO 2 at 37° C. The solutions were based on Joklik's Minimal Essential Medium supplemented with 1.2 mM MgSO 4 and 1 mM DL-carnitinine (MEM). They included a rinse solution (MEM), a digestion solution (MEM with 0.1% wt:vol fatty acid-free bovine albumin and 0.1 % collagenase), a calcium solution (MEM with 1 mM CaCl 2 and 1% fatty acid-free bovine albumin), and an incubation solution (MEM with 50 (JM CaCl 2 and 1% dialyzed bovine serum albumin). The heart first was perfused at 20° C for 5 minutes with rinse solution, then perfused at'37° C for 20 minutes with digestion solution. The ventricles were then removed, minced with scissors, and rinsed at 37° C for 15 minutes with calcium solution. Calcium solution was then removed by aspiration, and the tissue pieces were incubated at 37°C for 15 minutes with digestion solution in a shaking water bath. Dispersed eel Is were decanted into a plastic centrifuge tube, and the residual tissue shaken again with digestion solution. This resulted in almost total dispersion of the heart. The pooled myocytes were then filtered through a 185 /xm silkscreen mesh, were collected by gentle centrifugation, and were rinsed with incubation solution. The cells were again collected by gentle centrifugation and resuspended in incubation solution.
This method routinely yielded about 100 mg (dry weight) of myocytes, which corresponds to 2xlO 
Radioligand Binding
Myocytes (6x lOVassay) in 50 /AI incubation buffer were incubated for 45-60 minutes at 37° C with 1.3 [xM ATX II, 13 nM [ 3 H]BTXB (50 Ci/mmol), and 0.13 mM tetrodotoxin. Tetrodotoxin was added to prevent depolarization induced by sodium influx. Various concentrations of drugs and toxins were included in the incubations. Assays were done in parallel with tubes containing 0.4 mM aconitine to define nonspecific binding. Reactions were terminated by adding 10 ml of KHS buffer (Krebs-Henseleit-BS A; NaCl 127 mM, KC1 2.33 mM, KH 2 PO 4 1.30 mM, MgSO 4 1.23 mM, NaHCO 3 25 mM, glucose 10 mM, CaCl 2 50 /xM, BSA 1 %) equilibrated with 95% O 2 -5% CO 2 and incubated at 37° C for 1 minute, then filtered through a 24-mm filter (model GF-C, Whatman Bio Systems, Inc., Clifton, N.J.) and washed 4 times with 5 ml rinse buffer (Tris Cl 25 mM, pH 7.4; NaCl 130 mM, KC1 5.5 mM, MgSO, 0.8 mM, glucose 5.5 mM, CaCl 2 50 ^tM). The filters were then dried and counted in Econofluor scintillation fluid. The retained radioactivity represents [ 3 H]BTXB bound to myocytes. The rationale for the incubation and filtration conditions were described by Sheldon et al. 9 The conditions provide a maximal reduction in background and scatter with a minimal reduction in specific binding. The total wash time is 45 seconds. Initial control experiments showed that under these conditions less than 10% of the specifically bound [ 3 H]BTXB dissociated from the complex. Under these reaction conditions (13 nM [ 3 H]BTXB and 1.3 fiM ATX) about 60-75% of the total radioactivity retained on the filters is bound specifically to the receptor.
Drug Selection
Eight representative class I antiarrhythmic drugs were selected for study. They were selected if they were thought to be effective in treating ventricular tachycardia, if they were active themselves without necessarily invoking active metabolites, and if they possessed known therapeutic serum concentrations. (Procainamide is thought to be active even in the absence of its metabolite N-acetylprocainamide). Figure 1 . These results are representative of single experiments; each drug was studied 3-6 times. The inhibition by the drugs is dose dependent and follows a sigmoid curve characteristic of ligand binding to a single class of saturable sites.
Materials
In Table 1 , the therapeutic serum concentrations of Figure 2 as log(ICjo) versus log(serum concentration). Linear regression analysis of the log-log plot yields a slope of 
Drug Inhibition of [ 3 H]BTXB Binding is Reversible
The reversibility of lidocaine inhibition of Myocytes (6x lO^O /xl) were first incubated for 30 minutes at 37° C with 5 /xM ATX, 0.13 mM TTX, and either 39 /xM or 390 fjiWl lidocaine (Incubation 1), then diluted tenfold into 5 /xM ATX, 0.13 mM TTX, 13 nM [ 3 H]BTXB, and the indicated concentrations of lidocaine (Incubation 2). After a further 60 minutes incubation at 37° C, the myocytes were filtered and the specifically bound 
Antiarrhythmic Drug Binding is Stereospecific
The effect of the stereoisomers of tocainide and disopyramide on [ 3 H]BTXB binding was determined. /?-(-)-tocainide is significantly more potent than S-( + )-tocainide in prolonging conduction time in an ex vivo rabbit myocardium model (Sheldon et al, submitted) .This suggests that /?-(-)-tocainide would bind more tightly to the sodium channel than would S-( + )-tocainide, and the R-( -)-tocainide would more potently inhibit [ 3 H]BTXB binding than would S-( + )-tocainide. In radioligand studies, the IC,,, values (± SD) for the /?-(-) and S-( +) forms were 184 ± 8 and 546±37 /uM, respectively ( p<0.003).
In contrast, the stereoisomers of disopyramide have very similar concentration-dependent effects on the upstroke of the action potential in isolated dog Purkinje fibers. 17 When tested in the radioligand binding assay, the D and L optical isomers had IC,,, values of 122 ±45 and 109 ± 6 /JLM, respectively. Thus, the stereoisomers of tocainide had stereospecific effects on both prolonging conduction time and 
Discussion
Antiarrhythmic Drugs Bind to a Specific Site on Myocytes
Type I antiarrhythmic agents are thought to be effective because they block the sodium channel and prolong conduction time. How they do so is still unclear. Our understanding of this mechanism has evolved from the concept that these drugs function as general membrane depressants by interacting with the lipid bilayer and from more recent models invoking binding of the drugs to specific sites associated with sodium channels. 12 These models have not yet been assessed biochemically.
Using a radioligand binding technique, we have shown that type I antiarrhythmic drugs bind to specific sites on myocytes and that this binding inhibits the binding of toxins to the cardiac sodium channel. This strongly suggests that these drugs bind to a specific site associated with the sodium channel. Furthermore, the characteristics of this binding, i.e., it is saturable, reversible, and stereospecific, has rank order of potency similar to the drugs' pharmacologic potency, and occurs at pharmacologically relevant concentrations, suggest that this binding is involved in their pharmacologic effect." This is the first biochemical evidence that antiarrhythmic drugs bind to a specific receptor site associated with the cardiac sodium channel. The nature of the differences between the nerve and cardiac sodium channels, not only the mechanism of allosteric inhibition but also the relative affinities for ligands at the various sites, is an interesting and unresolved problem that merits further attention. Nonetheless, sodium channels of both neural and cardiac tissue share a common characteristic of blockade by drugs that allosterically inhibit the binding of [ 3 H]BTXB to the activated state. In review, type I antiarrhythmic drugs bind to specific sites related to cardiac sodium channels. The characteristics of their binding, i.e., being saturable, reversible, and stereospecific, having rank order of potency similar to the drugs' pharmacologic potency, and occurring at pharmacologically relevant concentrations, suggest that drug binding to this site is involved in their pharmacologic effect.
